Advertisement

Investigational New Drugs

, Volume 11, Issue 2–3, pp 151–159 | Cite as

VRCTC-310 — A novel compound of purified animal toxins separates antitumor efficacy from neurotoxicity

  • Robert A. Newman
  • Juan C. Vidal
  • Luis J. Viskatis
  • Jill Johnson
  • Martin A. Etcheverry
Preclinical Studies

Summary

Two purified animal venom toxins, crotoxin and cardiotoxin, have been combined to produce a unique natural product (VRCTC-310) currently under investigation as an antitumor agent by the National Cancer Institute.In vitro, it has demonstrated cytotoxic disease specificity and a unique mechanism of action when submitted to COMPARE analysis.In vivo, tolerance was developed to the neurotoxic properties of crotoxin which allowed comparison of several schedules of fixed and escalating daily i.m. doses to mice bearing s.c. Lewis Lung carcinoma. An 83% inhibition of tumor growth was achieved using an escalating dose schedule starting at 1.8 mg/kg and reaching 6.3 mg/kg/day on day 20. Although some irritation around the sites of i.m. injection was noted, animal weight loss was negligible and there were no other signs of adverse toxicity. This natural product represents a new, membrane interactive anticancer agent which produces a unique spectrum of cytotoxicityin vitro and which has demonstrated interestingin vivo antitumor efficacy.

Key words

VRCTC-310 animal venom phospholipase A2 cardiotoxin crotoxin Lewis lung carcinoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Tu AT, Giltner JB: Cytotoxic effects of snake venoms on KB and Yoshida sarcoma cells. Res Commun Chem Pathol Pharmacol 9:783, 1974Google Scholar
  2. 2.
    Chaim-Matyas A, Ovadia M: Cytotoxic activity of various snake venoms on melanoma B16F10 and chondrosarcoma. Life Sci 40:1601–1607, 1987Google Scholar
  3. 3.
    Braganca BM, Patel NT, Badrinath PG: Isolation of a cobra venom factor selectively cytotoxic to Yoshida sarcoma cells. Biochim Biophys Acta, 136:508, 1967.Google Scholar
  4. 4.
    Kaneda N, Hamaguchi M, Kojima K, Kaneshima H, Hayashi K: Action of cobra venom cardiotoxin on chick embryonal fibroblasts transformed with a temperature-sensitive mutant of Rous sarcoma virus. FEBS Lett 192:313–316, 1985Google Scholar
  5. 5.
    Chwetzoff S, Tsunawawa S, Sakiyama F, Menez A: Nigexine, a phospholipase A2 from cobra venom with cytotoxic properties not related to esterase activity. J Biol Chem 264:13289–13297, 1989Google Scholar
  6. 6.
    Corin RE, Viskatis LJ, Vidal JC, Etcheverry MA: Cytotoxicity of the crotoxin complex on murine erythroleukemia cells. Inv New Drugs. (In press)Google Scholar
  7. 7.
    Okamoto M, Viskatis LJ, de la Roza G, Vidal JC: Induction of tolerance to crotoxin in mice. J Pharmacol Exp Therap 265:41–46, 1993Google Scholar
  8. 8.
    Hendon RA, Fraenkel-Conrat H: Biological roles of the two components of crotoxin. Proc Natl Acad Sci USA 68: 1560–1563, 1971Google Scholar
  9. 9.
    Harvey A: Cardiotoxins from cobra venoms: Possible mechanisms of action. J Toxicol Tox Rev 4:41–69, 1985Google Scholar
  10. 10.
    Habermann E, Breithaupt H: Mini-Review: The crotoxin complex — An example of biochemical and pharmacological protein complementation. Toxicon 16:19–30, 1978Google Scholar
  11. 11.
    Monks A, Scudeiro D, Shehan P, Schoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J, Boyd M: Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl Cancer Institute 83:757–766, 1991Google Scholar
  12. 12.
    Seki C, Vidal JC, Barrio A: Purification of gyroxin from the South American rattlesnake (Crotalus durissus terrificus) venom. Toxicon 18:235–242, 1980Google Scholar
  13. 13.
    Aird SD, Kaiser II: Comparative studies of three rattlesnake toxins. Toxicon 23:361–374, 1985Google Scholar
  14. 14.
    Yang CC, King K, Sun TP: Chemical modification of lysine and histidine residues in phospholipase A2 from the venom ofNaja Naja Atra (Taiwan Cobra). Toxicon 19:645–659, 1981Google Scholar
  15. 15.
    Faure G, Bon C: Crotoxin, a phospholipase A2 neurotoxin from the South American rattlesnakeCrotalus Durissus Terrificus: Purification of several isoforms and comparison of their molecular structure and of their biological activities. Biochemistry 27:732–738, 1987.Google Scholar
  16. 16.
    Hodges SJ, Agbaji AS, Harvey AL, Hider RC: Cobra cardiotoxins — purification, effects on skeletal muscle and structure/activity relationships. Eur J Biochem 165:373–383, 1987Google Scholar
  17. 17.
    Meier J, Theakston RDG: Approximate LD50 determinations of snake venoms using eight to ten experimental animals. Toxicon 24:395–401, 1986Google Scholar
  18. 18.
    Gad S, Weil CS, Statistics, Experimental Design for the Toxicologist, Caldwell, NJ, Telford Press, 1988, pp. 72–74Google Scholar
  19. 19.
    Cochran WG, Cox GM, Experimental Designs, New York, John Wiley & Sons Inc., 1975, pp. 100–102Google Scholar
  20. 20.
    Lewin NE, DellAquila ML, Pettit GR, Blumberg PM, Warren BS: Binding of [3H]bryostatin 4 to protein kinase C. Biochem Pharmacol 43:2007–2014, 1992Google Scholar
  21. 21.
    Bai R, Friedman SJ, Pettit GR, Hamel E: Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules. Biochem Pharmacol 43:2637–2645, 1992Google Scholar
  22. 22.
    Hendon RA, Tu AT: The role of crotoxin subunits in tropical rattlesnake neurotoxic action. Biochim Biophys Acta 578:243–252, 1979Google Scholar
  23. 23.
    Rosenberg P: Phospholipases. In: Shier WT and Mebs D (eds), Handbook of Toxinology, New York, Marcel Dekker Inc., 1990, p. 87Google Scholar
  24. 24.
    Kini RM, Evans HJ: A model to explain the pharmacological effects of snake venom phospholipases A2. Toxicon 27: 613–635, 1989Google Scholar
  25. 25.
    Bougis P, Rochat H, Pieroni G, Verger R: Penetration of phospholipid monolayer by cardiotoxin. Biochemistry 20: 4915–4920, 1981Google Scholar
  26. 26.
    Condrea E: Membrane active polypeptides from snake venoms: Cardiotoxins and haemocytotoxins. Experientia 30:121–216, 1974Google Scholar
  27. 27.
    Louw AI, Visser L: The synergism of cardiotoxin and phospholipase A2 in hemolysis. Biochim Biophys Acta 512:163–171, 1978Google Scholar
  28. 28.
    Cheng YH, Hu CT, Yang JT: Membrane disintegration and hemolysis of human erythrocytes by snake venom cardiotoxin (a membrane-disruptive polypeptide). Biochem Int 8:329–338, 1984Google Scholar
  29. 29.
    Gopalakrishnakone P, Dempster DW, Hagwood BJ, Elder HY: Cellular and mitochondrial changes induced in the structure of murine skeletal muscle by crotoxin, a neurotoxic phospholipase A2 complex. Toxicon 22:85–98, 1984Google Scholar
  30. 30.
    Kouyoumdjian JA, Harris JB, Johnson MA: Muscle necrosis caused by the subunits of crotoxin. Toxicon 24:575–583, 1986Google Scholar
  31. 31.
    Lee CY, Chang CC, Chiu TH, Chiu PJS, Tseng TC, Lee SY: Pharmacological properties of cardiotoxin isolated from Formosan cobra venom. Naunyn Schmiedebergs Arch Pharmacol 259:360–374, 1968Google Scholar
  32. 32.
    Wang JP, Teng CM: Effect of anti-inflammatory drugs on the cardiotoxin induced hind-paw edema in rats. J Pharm Pharmacol 42:842–845, 1990Google Scholar
  33. 33.
    Condrea E, Barzilay A, Mager J: Role of cobra venom direct lytic factor and Ca2+ in promoting the activity of snake venom phospholipase A. Biochim Biophys Acta 210:65–73, 1970Google Scholar
  34. 34.
    Tu AT: Venoms, Chemistry and Molecular Biology, New York, John Wiley & Sons, 1977, p. 303Google Scholar
  35. 35.
    Paull KD, Shoemaker RH, Hodes L, Monks A, Scudeiro DA, Rubinstein L, Plowman J, Boyd R, Display, analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COM-PARE algorithm, J Natl Cancer Institute, 81:1088–1092, 1989Google Scholar

Copyright information

© Kluwer Academic Publishers 1993

Authors and Affiliations

  • Robert A. Newman
    • 1
  • Juan C. Vidal
    • 2
  • Luis J. Viskatis
    • 2
  • Jill Johnson
    • 3
  • Martin A. Etcheverry
    • 2
  1. 1.Department of Clinical InvestigationThe University of Texas, M.D. Anderson Cancer CenterHoustonUSA
  2. 2.Ventech Research Inc.CambridgeUSA
  3. 3.Drug Synthesis and Chemistry Branch, Division of Cancer TreatmentNational Cancer InstituteBethesdaUSA

Personalised recommendations